Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cell Oncol (Dordr)
Main Authors: Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
格式: Artigo
語言:Inglês
出版: Springer Netherlands 2015
主題:
Original Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://ncbi.nlm.nih.gov/pubmed/25665527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-015-0218-8
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍